The observed increased activity of 2h against PTP1B would make it possible for this potential allosteric site inhibitor) to enhance insulin sensitivity and thus act as an effective therapeutic for the treatment of T2D and obesity. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.